Tesofensine peptide is also known as:
- NS2330
- Tesofensine acetate
- Tesofensine tosylate
- (3R,4S)-4-[3-(4-chlorophenyl)propyl]piperidine-3-carboxylic acid
- (3R,4S)-4-[3-(4-chlorophenyl)propyl]piperidine-3-carboxylic acid acetate
- (3R,4S)-4-[3-(4-chlorophenyl)propyl]piperidine-3-carboxylic acid tosylate
Tesofensine peptide is a synthetic compound that is being developed for the treatment of obesity. It is a serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI), which means that it works by blocking the reuptake of serotonin, norepinephrine, and dopamine in the brain. This increases the levels of these neurotransmitters in the brain, which can lead to a number of effects, including:
- Reduced appetite
- Increased feelings of fullness
- Increased energy expenditure
- Improved mood
Tesofensine peptide has been shown to be effective in reducing body weight and body fat in clinical trials. In one study, participants who took tesofensine for 24 weeks lost an average of 12.6% of their body weight, compared to 6.5% in participants who took a placebo.
Tesofensine peptide is also well-tolerated in most people. The most common side effects are mild and go away on their own, such as dry mouth, nausea, and insomnia.
In addition to its potential for the treatment of obesity, tesofensine peptide is also being investigated for the treatment of other conditions, such as:
- Parkinson’s disease
- Alzheimer’s disease
- Attention deficit hyperactivity disorder (ADHD)
- Depression
However, more research is needed to confirm the safety and efficacy of tesofensine peptide for these conditions.
Tesofensine peptide is currently in Phase III clinical trials for the treatment of obesity. The results of these trials are expected to be released in 2023. If tesofensine peptide is approved by the FDA, it would be the first new drug for the treatment of obesity to be approved in over a decade.
It is important to note that tesofensine peptide is not currently approved for any use, and more research is needed to confirm its safety and efficacy for all of these conditions.
